[Federal Register Volume 87, Number 74 (Monday, April 18, 2022)]
[Notices]
[Page 22940]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-08212]



[[Page 22940]]

-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1296]


Notice of the Commission's Determination Not To Review an Initial 
Determination Terminating the Investigation on the Basis of Settlement; 
Termination of the Investigation; Certain Adalimumab, Processes for 
Manufacturing or Relating to Same, and Products Containing Same

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission has determined not to review the presiding administrative 
law judge's (``ALJ'') initial determination (``ID'') (Order No. 6) 
terminating the investigation on the basis of settlement. The 
investigation is terminated.

FOR FURTHER INFORMATION CONTACT: Amanda Pitcher Fisherow, Esq., Office 
of the General Counsel, U.S. International Trade Commission, 500 E 
Street SW, Washington, DC 20436, telephone (202) 205-2737. Copies of 
non-confidential documents filed in connection with this investigation 
may be viewed on the Commission's electronic docket (EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email 
[email protected]. General information concerning the Commission may 
also be obtained by accessing its internet server at https://www.usitc.gov. Hearing-impaired persons are advised that information on 
this matter can be obtained by contacting the Commission's TDD terminal 
on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation 
on January 31, 2022, based on a complaint filed by AbbVie Inc. of 
Chicago, Illinois, AbbVie Biotechnology Ltd of Bermuda, and AbbVie 
Operations Singapore Pte. Ltd. of Singapore. 87 FR 4912-13 (Jan. 31, 
2022). The complaint, as supplemented, alleged violations of section 
337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, based upon 
the importation into the United States, the sale of certain adalimumab, 
processes for manufacturing or relating to same, and products 
containing same by reason of the misappropriation of trade secrets and 
tortious interference with contractual relations, the threat or effect 
of which is to destroy or substantially injure an industry in the 
United States. The complaint, as amended, further alleged that a 
domestic industry exists. The notice of investigation named as 
respondents Alvotech hf. of Iceland; Alvotech Germany GmbH of Germany; 
Alvotech Swiss AG of Zurich, Switzerland; Alvotech USA Inc. of 
Arlington, Virginia, and Ivers-Lee AG of Bern, Switzerland. Id. The 
Office of Unfair Import Investigations (``OUII'') was also named as a 
party to the investigation. Id.
    On March 11, 2022, the private parties jointly moved to terminate 
the investigation on the basis of settlement. OUII filed a response in 
support of the motion. On March 28, 2022, the presiding ALJ issued 
Order No. 6, granting the joint motion. The ID found that the parties 
complied with Commission Rule 210.21(b). The ID also found that 
termination of the investigation will not adversely affect the public 
interest. No one petitioned for review of the ID.
    The Commission has determined not to review the ID. The 
investigation is terminated.
    The Commission vote for this determination took place on April 12, 
2022.
    The authority for the Commission's determination is contained in 
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and 
in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR 
part 210).

    By order of the Commission.

    Issued: April 12, 2022.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2022-08212 Filed 4-15-22; 8:45 am]
BILLING CODE 7020-02-P